Literature DB >> 31492773

Empirical evaluation of SUCRA-based treatment ranks in network meta-analysis: quantifying robustness using Cohen's kappa.

Caitlin H Daly1, Binod Neupane1, Joseph Beyene1,2, Lehana Thabane1,3, Sharon E Straus4,5, Jemila S Hamid6,7.   

Abstract

OBJECTIVE: To provide a framework for quantifying the robustness of treatment ranks based on Surface Under the Cumulative RAnking curve (SUCRA) in network meta-analysis (NMA) and investigating potential factors associated with lack of robustness.
METHODS: We propose the use of Cohen's kappa to quantify the agreement between SUCRA-based treatment ranks estimated through NMA of a complete data set and a subset of it. We illustrate our approach using five published NMA data sets, where robustness was assessed by removing studies one at a time.
RESULTS: Overall, SUCRA-based treatment ranks were robust to individual studies in the five data sets we considered. We observed more incidences of disagreement between ranks in the networks with larger numbers of treatments. Most treatments moved only one or two ranks up or down. The lowest quadratic weighted kappa estimate observed across all networks was in the network with the smallest number of treatments (4), where weighted kappa=40%. In the network with the largest number of treatments (12), the lowest observed quadratic weighted kappa=89%, reflecting a small shift in this network's treatment ranks overall. Preliminary observations suggest that a study's size, the number of studies making a treatment comparison, and the agreement of a study's estimated treatment effect(s) with those estimated by other studies making the same comparison(s) may explain the overall robustness of treatment ranks to studies.
CONCLUSIONS: Investigating robustness or sensitivity in an NMA may reveal outlying rank changes that are clinically or policy-relevant. Cohen's kappa is a useful measure that permits investigation into study characteristics that may explain varying sensitivity to individual studies. However, this study presents a framework as a proof of concept and further investigation is required to identify potential factors associated with the robustness of treatment ranks using more extensive empirical evaluations. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  SUCRA; kappa; mixed-treatment comparisons; network meta-analysis; ranks; robustness

Mesh:

Year:  2019        PMID: 31492773      PMCID: PMC6731799          DOI: 10.1136/bmjopen-2018-024625

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  30 in total

1.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.

Authors:  Georgia Salanti; A E Ades; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2010-08-05       Impact factor: 6.437

Review 2.  Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.

Authors:  Vincent Thijs; Robin Lemmens; Steffen Fieuws
Journal:  Eur Heart J       Date:  2008-03-17       Impact factor: 29.983

3.  How to use an article reporting a multiple treatment comparison meta-analysis.

Authors:  Edward J Mills; John P A Ioannidis; Kristian Thorlund; Holger J Schünemann; Milo A Puhan; Gordon H Guyatt
Journal:  JAMA       Date:  2012-09-26       Impact factor: 56.272

4.  Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit.

Authors:  J Cohen
Journal:  Psychol Bull       Date:  1968-10       Impact factor: 17.737

5.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

Authors:  William J Elliott; Peter M Meyer
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

Review 6.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

Authors:  Andrea Cipriani; Toshiaki A Furukawa; Georgia Salanti; John R Geddes; Julian Pt Higgins; Rachel Churchill; Norio Watanabe; Atsuo Nakagawa; Ichiro M Omori; Hugh McGuire; Michele Tansella; Corrado Barbui
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

Review 7.  Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients.

Authors:  L J Middleton; R Champaneria; J P Daniels; S Bhattacharya; K G Cooper; N H Hilken; P O'Donovan; M Gannon; R Gray; K S Khan; J Abbott; J Barrington; S Bhattacharya; M Y Bongers; J-L Brun; R Busfield; M Sowter; T J Clark; J Cooper; K G Cooper; S L Corson; K Dickersin; N Dwyer; M Gannon; J Hawe; R Hurskainen; W R Meyer; H O'Connor; S Pinion; A M Sambrook; W H Tam; I A A van Zon-Rabelink; E Zupi
Journal:  BMJ       Date:  2010-08-16

8.  Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.

Authors:  William L Baker; Erica L Baker; Craig I Coleman
Journal:  Pharmacotherapy       Date:  2009-08       Impact factor: 4.705

9.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18

10.  Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials.

Authors:  Ludovic Trinquart; Adeline Abbé; Philippe Ravaud
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

View more
  4 in total

1.  Rapid identification of SARS-CoV-2 in the point-of-care using digital PCR-based Dr. PCR™ Di20K COVID-19 Detection Kit without viral RNA extraction.

Authors:  Wonseok Shin; Cherl-Joon Lee; Yong-Moon Lee; Young-Bong Choi; Seyoung Mun; Kyudong Han
Journal:  Genes Genomics       Date:  2022-03-30       Impact factor: 2.164

2.  Comparative Efficacy and Acceptability of Anti-inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis.

Authors:  Xiaoyi Hang; Yijie Zhang; Jingjing Li; Zhenzhen Li; Yi Zhang; Xuanhao Ye; Qisheng Tang; Wenjun Sun
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

3.  miRNA-21 may serve as a promising noninvasive marker of glioma with a high diagnostic performance: a pooled analysis of 997 patients.

Authors:  Xinli Zhao; Zhihong Xiao; Bin Li; Hongwei Li; Bo Yang; Tian Li; Zubing Mei
Journal:  Ther Adv Med Oncol       Date:  2021-01-31       Impact factor: 8.168

4.  Diagnostic evaluation of qRT-PCR-based kit and dPCR-based kit for COVID-19.

Authors:  Cherl-Joon Lee; Wonseok Shin; Seyoung Mun; Minjae Yu; Young-Bong Choi; Dong Hee Kim; Kyudong Han
Journal:  Genes Genomics       Date:  2021-09-15       Impact factor: 1.839

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.